CN111116500B - Purification method of Resinard key intermediate - Google Patents

Purification method of Resinard key intermediate Download PDF

Info

Publication number
CN111116500B
CN111116500B CN201911388222.4A CN201911388222A CN111116500B CN 111116500 B CN111116500 B CN 111116500B CN 201911388222 A CN201911388222 A CN 201911388222A CN 111116500 B CN111116500 B CN 111116500B
Authority
CN
China
Prior art keywords
mixed solvent
key
purifying
stirring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911388222.4A
Other languages
Chinese (zh)
Other versions
CN111116500A (en
Inventor
夏中宁
吴进
王仕伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Xin Kai Yuan Pharmaceutical Technology Co ltd Hainan Branch
Original Assignee
Beijing Xin Kai Yuan Pharmaceutical Technology Co ltd Hainan Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xin Kai Yuan Pharmaceutical Technology Co ltd Hainan Branch filed Critical Beijing Xin Kai Yuan Pharmaceutical Technology Co ltd Hainan Branch
Priority to CN201911388222.4A priority Critical patent/CN111116500B/en
Publication of CN111116500A publication Critical patent/CN111116500A/en
Application granted granted Critical
Publication of CN111116500B publication Critical patent/CN111116500B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides a method for purifying a key intermediate of Reisinad, which comprises the following steps: and stirring and dissolving the key intermediate crude product in a mixed solvent of alcohols and esters, adding activated carbon, filtering, cooling and crystallizing, filtering, and drying under reduced pressure to obtain a high-purity intermediate compound. The method has good refining effect, high yield and purity of the refined target product, and better ensures the stability of the next process; the refining process is simple, the used solvent is common and easy to recover, and the industrial operation is greatly simplified, so that the method is suitable for industrial mass production.

Description

Purification method of Resinard key intermediate
Technical Field
The invention relates to the technical field of preparation of Raschindde medicaments, in particular to a purification method of a Raschindde key intermediate.
Background
Hyperuricemia (HUA) is one of the important components of metabolic syndrome, is closely related to gout, and is also a risk factor of hypertension, chronic kidney disease, dyslipidemia, diabetes, cardiovascular disease and the like. The prevalence rate of the HUA in developed western countries is 15-20%, and in recent years, with the improvement of the living standard of China, the change of the dietary structure and the prolonging of the average life span, the prevalence rate of the HUA is increased year by year. It is estimated that the number of patients with the present HUA in China is nearly 1.2 million, and about 1700 million patients with gout are. Gout is a chronic metabolic disease mainly characterized by hyperuricemia and pain caused by deposition of monosodium urate (MSU) on joints and other parts, and is mainly caused by purine metabolic disorder and/or uric acid excretion disorder.
Rexinard (Lesinurad), chemical name 2- [ [ 5-bromo-4- (4-cyclopropyl-1-naphthalen) -4H-1,2, 4-triazol-3-yl ] thio ] acetic acid, was approved by the Food and Drug Administration (FDA) on the market at 12/22 of 2015, and by the european drug administration (EMA) on 18 of 12/18 of the year, recommended approval for the drug to market in the european union. Racinadine is the first approved urate reabsorption transporter (URAT1) inhibitor worldwide, in combination with xanthine oxidase inhibitors for the treatment of hyperuricemia-associated gout.
The key intermediate disclosed in the original patent CN104736522A is prepared by taking 4-cyclopropyl-1-naphthyl isothiocyanate as a starting material through cyclization and then carrying out substitution reaction with methyl bromoacetate. The obtained methyl 2- (4- (1-cyclopropyl-naphthalene-4-yl) -4H-1,2, 4-triazole-3-yl-sulfenyl) acetate (compound (4) synthesized by the method has low purity, and the system has dark color when the compound is dissolved by a reaction solvent in the next step.
A large number of experiments show that impurities can seriously affect the bromination free radical reaction because the bromination reaction is the free radical reaction, so that the reaction of the intermediate (4) is incomplete, and the quality of Raschild is affected.
The synthesis route of the Racinade mainly comprises the following steps:
Figure BDA0002344162090000021
compound (4) was synthesized according to the method reported in patent CN104736522A, followed by synthesis of Ravinard. However, it is difficult to obtain acceptable rasidone products according to the above method. Therefore, a purification method for purifying the compound (4) is urgently required.
Disclosure of Invention
The invention aims to provide a refining method of 2- (4- (1-cyclopropyl naphthalene-4-yl) -4H-1,2, 4-triazole-3-yl sulfenyl) methyl acetate which is a key intermediate of Reisinad aiming at the defects in the prior art, so that the color and impurities in the compound (4) are reduced, and the product quality is improved.
The technical scheme of the invention is realized as follows: the crude product of the compound (4) can be synthesized by the prior art, namely, the synthesis is carried out according to the route disclosed in the original patent CN104736522A, namely, 4-cyclopropyl-1-naphthyl isothiocyanate is taken as a starting material, and the crude product is obtained by cyclization and substitution reaction with methyl bromoacetate, and has dark color, more impurities and no purification step. The synthetic route is as follows:
Figure BDA0002344162090000022
a method for purifying a key Leishard intermediate comprises the following steps: stirring and dissolving the key intermediate crude product in a mixed solvent of alcohols and esters, adding activated carbon, filtering, cooling and crystallizing, filtering, and drying under reduced pressure to obtain a high-purity intermediate compound (2- (4- (1-cyclopropyl naphthalene-4-yl) -4H-1,2, 4-triazole-3-yl sulfenyl) methyl acetate), wherein the structural formula of the compound is shown as the formula (4):
Figure BDA0002344162090000031
further, the mixed solvent is prepared by mixing an alcohol organic solvent and an ester organic solvent, wherein the alcohol organic solvent is at least one of methanol, ethanol and isopropanol, and the ester organic solvent is at least one of ethyl acetate, butyl acetate and isopropyl acetate.
Further, the mixed solvent is a mixed solvent of ethyl acetate and isopropanol.
Further, in the mixed solvent, the volume ratio of the alcohol organic solvent to the ester organic solvent is 10-5: 1.
furthermore, the volume usage of the mixed solvent is 5-15 times of the mass ml/g of the crude intermediate product.
Furthermore, the volume consumption of the mixed solvent is 8-10 times of the mass ml/g of the crude intermediate product.
Further, the dissolving temperature is 50-75 ℃.
Further, the dissolving temperature is 60-65 ℃.
Further, the crystallization temperature is-10-30 ℃.
Further, the crystallization temperature is 0-10 ℃.
Further, the method for purifying the key intermediate of the Raschild sodium comprises the following steps: adding an 8:1 alcohol and ester mixed solvent into the crude product of the compound (4), and controlling the mass-volume ratio within 8-10 times; heating to 60-65 ℃, stirring for dissolving, adding activated carbon, stirring for 10-15 min, filtering while hot, slowly cooling to 0-10 ℃, crystallizing for 3-5 h, performing suction filtration to obtain a filter cake, and performing vacuum reduced pressure drying on the filter cake at 50 ℃ for 6-8 h to obtain a white solid, namely the high-purity compound.
The high performance liquid analysis method used was as follows:
a chromatographic column: kromasil C184.6X 150mm, 5 μm
Mobile phase: a: 0.02mol/L potassium dihydrogen phosphate (adjusted to pH 3.0 with phosphoric acid) B: methanol
The gradient elution procedure was as follows:
time (minutes) Mobile phase A (%) Mobile phase B (%)
0 90 10
5 90 10
15 70 30
35 45 55
80 15 85
95 15 85
97 90 10
107 90 10
Column temperature: 35 deg.C
Detection wavelength: 226nm
Diluent agent: acetonitrile
Sample concentration: 0.5mg/ml
Flow rate: 1.0ml/min
Sample introduction amount: 5 μ l
Compared with the prior art, the invention has the beneficial effects that:
(1) according to the invention, after refining the key intermediate of Racinidide, the impurity content is effectively reduced, the purity of the obtained target compound 2- (4- (1-cyclopropyl naphthalene-4-yl) -4H-1,2, 4-triazole-3-yl sulfenyl) methyl acetate is high, the adverse effect of incomplete reaction in the next step caused by impurities is reduced, the process stability in the next step is better ensured, the quality of Racinidide is improved, and a high-purity product is obtained.
(2) The method has the advantages of good refining effect, high yield and purity of the refined target product, simple refining process, common used solvent and easy recovery, greatly simplifies the industrial operation, and is suitable for industrial mass production.
Drawings
FIG. 1 is an HPLC chromatogram of the crude product of reference example 1.
FIG. 2 is an HPLC chromatogram of bromide in reference example 2.
FIG. 3 is an HPLC chromatogram of the purification of example 2.
FIG. 4 is an HPLC chromatogram of test example 1.
Detailed Description
In order to better understand the technical content of the invention, specific examples are provided below to further illustrate the invention.
The experimental methods used in the examples of the present invention are all conventional methods unless otherwise specified.
The materials, reagents and the like used in the examples of the present invention can be obtained commercially without specific description.
Reference example 1
The crude product of the compound (4) is synthesized into the crude product of the intermediate compound (4) according to the synthesis method of the patent publication CN104736522A, namely 4-cyclopropyl-1-naphthyl isothiocyanate is used as a starting material, and is obtained by cyclization and substitution reaction with methyl bromoacetate, so that the crude product is dark in color and more in impurities, and the purity of the crude product is 84.876%. The synthetic route is as follows:
Figure BDA0002344162090000051
reference example 2: synthesis of methyl 2- (5-bromo-4- (1-cyclopropylnaphthalen-4-yl) -4H-1,2, 4-triazol-3-ylthio) acetate
Taking 8.0g of the crude compound (4) obtained in the reference example 1 and 64ml of tetrahydrofuran, starting stirring, heating to a temperature T of 30-35 ℃, and stirring until the compound is dissolved; adding 6.4g of NBS, stirring and reacting for 3-4 h, after the reaction is finished, cooling to 0-5 ℃ of T, adding 40ml of toluene, dropwise adding 40ml of purified water, controlling the temperature to be not more than 7 ℃, stirring for 10min after dropwise adding, and standing for liquid separation; cooling the organic phase to 0-5 ℃, dropwise adding 40ml of 3% sodium bisulfite solution, keeping the temperature below 10 ℃, stirring for 20min after dropwise adding, standing for liquid separation, and collecting the organic phase; heating to 18-25 ℃ by using an organic camera, adding 40ml of 7% sodium bicarbonate solution, stirring for 10min, standing for liquid separation, collecting an organic phase, concentrating, and drying to obtain the Raschild product, wherein the purity of the Raschild product is detected to be 96.443%.
Example 1
Taking 10.0g of the crude compound (4) obtained in reference example 1, adding a 6-time mixed solvent of ethanol and ethyl acetate (ethanol: ethyl acetate: 10: 1), heating to 60-65 ℃, stirring for dissolving, adding 3.0g of activated carbon, keeping the temperature, stirring for 10-15 min, filtering, slowly cooling to 0-10 ℃, stirring for 3-5 h, performing suction filtration, and performing vacuum drying at 50 ℃ under reduced pressure for 6-8 h to obtain 8.51g of a white solid, namely the high-purity compound (I), wherein the yield is 85.1%.
Example 2
Taking 10.0g of the crude compound (4) obtained in reference example 1, adding 9 times (90ml) of isopropanol and ethyl acetate mixed solvent (isopropanol: ethyl acetate: 8: 1), heating to 60-65 ℃, stirring for dissolving, adding 3.0g of activated carbon, keeping the temperature and stirring for 10-15 min, filtering, slowly cooling to 0-10 ℃, stirring for 3-5 h, performing suction filtration, and performing vacuum drying at 50 ℃ for 6-8 h under reduced pressure to obtain 8.45g of white solid, namely the high-purity compound (4), wherein the yield is 84.5%.
Example 3
Taking 10.0g of the crude compound (4) obtained in reference example 1, adding 9 times (90ml) of a mixed solvent of ethanol and butyl acetate (ethanol: butyl acetate: 9: 1), heating to 60-65 ℃, stirring for dissolving, adding 3.0g of activated carbon, keeping the temperature, stirring for 10-15 min, filtering, slowly cooling to 0-10 ℃, stirring for 3-5 h, performing suction filtration, and performing vacuum drying at 50 ℃ for 6-8 h under reduced pressure to obtain 8.65g of a white solid, namely the high-purity compound (4), wherein the yield is 86.5%.
Example 4
Taking 10.0g of the crude compound (4) obtained in reference example 1, adding 9 times (90ml) of isopropanol-butyl acetate mixed solvent (isopropanol: butyl acetate: 7: 1), heating to 60-65 ℃, stirring for dissolving, adding 3.0g of activated carbon, keeping the temperature and stirring for 10-15 min, filtering, slowly cooling to 0-10 ℃, stirring for 3-5 h, performing suction filtration, and performing vacuum drying at 50 ℃ for 6-8 h under reduced pressure to obtain 8.57g of white solid, namely the high-purity compound (4), wherein the yield is 85.7%.
Example 5
Taking 10.0g of the crude compound (4) obtained in reference example 1, adding 10 times (100ml) of a mixed solvent of isopropanol and isopropyl acetate (isopropanol: isopropyl acetate: 7: 1), heating to 60-65 ℃, stirring for dissolving, adding 3.0g of activated carbon, keeping the temperature and stirring for 10-15 min, filtering, slowly cooling to 0-10 ℃, stirring for 3-5 h, performing suction filtration, and performing vacuum drying at 50 ℃ for 6-8 h under reduced pressure to obtain 8.53g of a white solid, namely the high-purity compound (4), wherein the yield is 85.3%.
Example 6
Taking 10.0g of the crude compound (4) obtained in reference example 1, adding a 7-fold (70ml) amount of a mixed solvent of methanol and isopropyl acetate (methanol: isopropyl acetate: 10: 1), heating to 60-65 ℃, stirring for dissolving, adding 3.0g of activated carbon, keeping the temperature, stirring for 10-15 min, filtering, slowly cooling to 0-10 ℃, stirring for 3-5 h, performing suction filtration, and performing vacuum drying at 50 ℃ for 6-8 h under reduced pressure to obtain 8.46g of a white solid, namely the high-purity compound (4), wherein the purity is 99.2%, and the yield is 84.6%.
Test example 1: synthesis of methyl 2- (5-bromo-4- (1-cyclopropylnaphthalen-4-yl) -4H-1,2, 4-triazol-3-ylthio) acetate
Taking 8.0g of the purified product of the compound (4) obtained in example 3 and 64ml of tetrahydrofuran, starting stirring, heating to the temperature of between 30 and 35 ℃, and stirring until the mixture is dissolved; adding 6.4g of NBS, stirring and reacting for 3-4 h, after the reaction is finished, cooling to 0-5 ℃ of T, adding 40ml of toluene, dropwise adding 40ml of purified water, controlling the temperature to be not more than 7 ℃, stirring for 10min after dropwise adding, and standing for liquid separation; cooling the organic phase to 0-5 ℃, dropwise adding 40ml of 3% sodium bisulfite solution, keeping the temperature below 10 ℃, stirring for 20min after dropwise adding, standing for liquid separation, and collecting the organic phase; heating to 18-25 ℃ by using an organic camera, adding 40ml of 7% sodium bicarbonate solution, stirring for 10min, standing for liquid separation, collecting an organic phase, concentrating and drying to obtain the Raschild product, wherein the purity of the Raschild product is detected to be 99.940%.
The intermediate compounds before and after purification of reference example and examples 1 to 6 and reference example 2 and test example 1 were weighed and tested for purity, wherein,
yield of fine product is 100% of weight of fine product after purification/weight of intermediate coarse body;
percent reduction of impurities (pre-purification impurity content-post-purification impurity content)/pre-purification impurity content 100%.
Figure BDA0002344162090000081
The results show that the purification method provided by the invention, examples 1-6, can be used for refining the crude product of the key intermediate of Ravinard, and can effectively reduce the impurity content and obtain the target product with high purity on the premise of high yield of the refined product.
Furthermore, experimental example 1 the purity of the product of rasidone obtained from the preparation of the purified product of the present invention (99.940%) was much higher than that of the product of rasidone prepared without purification in reference example 2 (96.443%), and the content of impurities was reduced by 98.31%.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims (6)

1. A method for purifying a key Leishard intermediate is characterized by comprising the following steps: stirring and dissolving the key intermediate crude product in a mixed solvent of alcohols and esters, adding activated carbon, filtering, cooling and crystallizing, filtering, and drying under reduced pressure to obtain a high-purity intermediate compound, wherein the structural formula of the compound is as shown in formula (4):
Figure FDA0003023285140000011
in the mixed solvent, the volume ratio of the alcohol organic solvent to the ester organic solvent is 10-5: 1; the volume consumption of the mixed solvent is 5-15 times of the mass ml/g of the intermediate crude product; the dissolving temperature is 60-65 ℃.
2. The method for purifying the key Leishard intermediate as claimed in claim 1, wherein the mixed solvent is prepared by mixing an alcohol organic solvent and an ester organic solvent, the alcohol organic solvent is at least one of methanol, ethanol and isopropanol, and the ester organic solvent is at least one of ethyl acetate, butyl acetate and isopropyl acetate.
3. The method for purifying the key Leishard intermediate as claimed in claim 2, wherein the mixed solvent is a mixed solvent of ethyl acetate and isopropanol.
4. The method for purifying the key intermediate of Reisinard as claimed in claim 1, wherein the volume usage of the mixed solvent is 8-10 times of the crude intermediate mass ml/g.
5. The method for purifying the key Leishina intermediate as claimed in claim 1 or 4, wherein the crystallization temperature is-10 to 30 ℃.
6. The method for purifying the key Leishina intermediate as claimed in claim 5, wherein the crystallization temperature is 0-10 ℃.
CN201911388222.4A 2019-12-30 2019-12-30 Purification method of Resinard key intermediate Active CN111116500B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911388222.4A CN111116500B (en) 2019-12-30 2019-12-30 Purification method of Resinard key intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911388222.4A CN111116500B (en) 2019-12-30 2019-12-30 Purification method of Resinard key intermediate

Publications (2)

Publication Number Publication Date
CN111116500A CN111116500A (en) 2020-05-08
CN111116500B true CN111116500B (en) 2021-06-08

Family

ID=70505761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911388222.4A Active CN111116500B (en) 2019-12-30 2019-12-30 Purification method of Resinard key intermediate

Country Status (1)

Country Link
CN (1) CN111116500B (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524440A (en) * 2013-10-15 2014-01-22 苏州鹏旭医药科技有限公司 Preparation method of gout curative medicine Lesinurad and midbody of Lesinurad
CN104736522A (en) * 2012-07-03 2015-06-24 阿迪亚生命科学公司 Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl) -4H-1,2,4-triazol-3-ylthio) acetic acid
CN105017168A (en) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylsulfanyl]-methyl acetate
CN105175348A (en) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 Preparation method for lesinurad
CN105263913A (en) * 2013-06-14 2016-01-20 广东东阳光药业有限公司 Thio-1,2,4-triazole derivatives and method for preparing the same
CN105294585A (en) * 2014-07-02 2016-02-03 成都海创药业有限公司 Compound for treating gout
CN105399694A (en) * 2015-12-11 2016-03-16 浙江京新药业股份有限公司 Axially chiral enantiomers of drug Lesinurad
CN105906576A (en) * 2016-06-12 2016-08-31 成都百裕制药股份有限公司 Method for preparing lesinurad intermediate
EP3281941A1 (en) * 2016-08-11 2018-02-14 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
CN109970667A (en) * 2017-12-27 2019-07-05 徐州万邦金桥制药有限公司 A kind of refining methd of the western Nader of thunder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736522A (en) * 2012-07-03 2015-06-24 阿迪亚生命科学公司 Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl) -4H-1,2,4-triazol-3-ylthio) acetic acid
CN105263913A (en) * 2013-06-14 2016-01-20 广东东阳光药业有限公司 Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440A (en) * 2013-10-15 2014-01-22 苏州鹏旭医药科技有限公司 Preparation method of gout curative medicine Lesinurad and midbody of Lesinurad
CN105294585A (en) * 2014-07-02 2016-02-03 成都海创药业有限公司 Compound for treating gout
CN105017168A (en) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylsulfanyl]-methyl acetate
CN105175348A (en) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 Preparation method for lesinurad
CN105399694A (en) * 2015-12-11 2016-03-16 浙江京新药业股份有限公司 Axially chiral enantiomers of drug Lesinurad
CN105906576A (en) * 2016-06-12 2016-08-31 成都百裕制药股份有限公司 Method for preparing lesinurad intermediate
EP3281941A1 (en) * 2016-08-11 2018-02-14 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
CN109970667A (en) * 2017-12-27 2019-07-05 徐州万邦金桥制药有限公司 A kind of refining methd of the western Nader of thunder

Also Published As

Publication number Publication date
CN111116500A (en) 2020-05-08

Similar Documents

Publication Publication Date Title
US11434210B2 (en) Method for synthesizing valsartan
CN104447600B (en) A kind of Preparation Method And Their Intermediate impurity of Parecoxib sodium compound, preparation method and application
WO2021022788A1 (en) Composition of 5-fluorouracil and refining method therefor
US10793512B2 (en) Preparation method for high purity racemic adrenaline
CN107573330B (en) Preparation method of topiroxostat
CN109134430B (en) Method for preparing rabeprazole impurity by HPLC (high performance liquid chromatography)
CN114249711A (en) Method for preparing nicotine by resolution
CN111116500B (en) Purification method of Resinard key intermediate
WO2011107903A1 (en) Highly pure mosapride citrate dihydrate and processes for its preparation
CN110467580B (en) Resolution method of Raxinard axis chiral enantiomer
CN111153862B (en) Raisinard refining method
CN114213343B (en) Preparation and purification methods of celecoxib intermediate
CN109912531A (en) The preparation method of high-purity Febustat
CN114213306A (en) Preparation method of brivaracetam acid impurity
CN112778223A (en) Preparation method of Raschindde oxidation impurities
CN111253330A (en) Novel crystal form of sartan drug, preparation method and application thereof
CN111978259B (en) Allopurinol impurity F and preparation method thereof
CN111320588B (en) Method for purifying Lesinurad
CN115448847B (en) Salbutamol in salbutamol Process for the preparation of intermediates
CN103588775B (en) Pralatrexate degradation impurity and preparation method thereof
CN114573411B (en) Preparation method of (S) -1,2,3, 4-tetrahydro-1-naphthoic acid
CN104119326B (en) Method for preparing azilsartan
CN116813594A (en) Letermopevir related substance P, preparation method and detection method thereof
CN115057846A (en) Preparation method of trelagliptin dimer
RU2644674C1 (en) Method for obtaining 3,3',3'',3'''-(3,8,13,17-tetramethylporphyrin-2,7,12,18-tetrayl) tetrapropionic acid (coproporphyrin)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A Purification Method of the Key Intermediate of Racenard

Effective date of registration: 20220929

Granted publication date: 20210608

Pledgee: Haikou Xiuying Sub branch of Bank of China Ltd.

Pledgor: Beijing Xin Kai Yuan Pharmaceutical Technology Co.,Ltd. Hainan branch

Registration number: Y2022980017059